Tuberculosis of genitourinary system
ICD-10 A18.1 is a used to indicate a diagnosis of tuberculosis of genitourinary system.
Tuberculosis of the genitourinary system is a rare but serious manifestation of extrapulmonary tuberculosis, primarily caused by Mycobacterium tuberculosis. This condition can affect various parts of the urinary tract, including the kidneys, ureters, bladder, and reproductive organs. Patients may present with symptoms such as hematuria (blood in urine), dysuria (painful urination), flank pain, and urinary frequency. Diagnosis typically involves a combination of clinical evaluation, imaging studies such as ultrasound or CT scans, and microbiological tests, including urine cultures and PCR testing for Mycobacterium tuberculosis. Treatment usually consists of a multi-drug regimen similar to that used for pulmonary tuberculosis, including isoniazid, rifampin, pyrazinamide, and ethambutol, administered over a period of 6 to 12 months. Monitoring for drug resistance is crucial, as resistance can complicate treatment and prolong recovery. Public health implications are significant, as tuberculosis is a communicable disease, necessitating contact tracing and isolation procedures for active cases to prevent transmission. Regular follow-up and adherence to treatment protocols are essential to ensure successful outcomes and minimize the risk of recurrence.
Detailed clinical notes on symptoms, diagnostic tests, and treatment plans.
Patients presenting with unexplained hematuria or recurrent urinary tract infections.
Consideration of drug resistance and the need for specialized treatment regimens.
Comprehensive records of urological evaluations and imaging studies.
Management of renal tuberculosis and its complications.
Coordination with infectious disease specialists for treatment management.
Used when testing urine samples for tuberculosis.
Document the reason for testing and any relevant clinical findings.
Infectious disease specialists should ensure proper specimen collection and handling.
Common symptoms include hematuria, dysuria, flank pain, and urinary frequency. Patients may also experience systemic symptoms such as fever and weight loss.
Diagnosis typically involves urine cultures, imaging studies, and sometimes biopsy to confirm the presence of Mycobacterium tuberculosis.
Treatment usually involves a multi-drug regimen similar to that for pulmonary tuberculosis, lasting 6 to 12 months, with close monitoring for drug resistance.
Public health measures include contact tracing, isolation of active cases, and ensuring adherence to treatment to prevent transmission.
